Evolutionary Tree Capital Management LLC Has $2.41 Million Stake in Krystal Biotech, Inc. (NASDAQ:KRYS)

Key Points

• Evolutionary Tree Capital Management LLC increased its stake in Krystal Biotech by 24.7% during the 1st quarter, now holding a position valued at approximately $2.41 million.
• Insider Suma Krishnan sold 13,435 shares for a total of about $2.02 million, representing a 0.92% decrease in ownership.
• Analysts have mixed ratings on Krystal Biotech, with target prices ranging from $176.00 to $240.00, indicating a generally positive outlook with an average rating of "Buy."

Evolutionary Tree Capital Management LLC grew its stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 24.7% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,343 shares of the company's stock after acquiring an additional 2,643 shares during the period. Krystal Biotech accounts for approximately 2.8% of Evolutionary Tree Capital Management LLC's holdings, making the stock its 16th largest position. Evolutionary Tree Capital Management LLC's holdings in Krystal Biotech were worth $2,406,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of KRYS. LPL Financial LLC boosted its holdings in shares of Krystal Biotech by 156.8% during the 4th quarter. LPL Financial LLC now owns 2,946 shares of the company's stock worth $462,000 after buying an additional 1,799 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Krystal Biotech by 18.7% during the fourth quarter. JPMorgan Chase & Co. now owns 151,835 shares of the company's stock worth $23,786,000 after acquiring an additional 23,934 shares during the period. Norges Bank bought a new position in shares of Krystal Biotech during the fourth quarter worth approximately $34,391,000. Alliancebernstein L.P. boosted its stake in Krystal Biotech by 4.7% in the 4th quarter. Alliancebernstein L.P. now owns 31,120 shares of the company's stock valued at $4,875,000 after purchasing an additional 1,400 shares during the period. Finally, OLD Mission Capital LLC acquired a new position in Krystal Biotech in the 4th quarter valued at $293,000. Institutional investors own 86.29% of the company's stock.

Insider Buying and Selling at Krystal Biotech

In related news, insider Suma Krishnan sold 1,389 shares of the company's stock in a transaction that occurred on Wednesday, July 16th. The stock was sold at an average price of $150.00, for a total value of $208,350.00. Following the sale, the insider directly owned 1,508,056 shares in the company, valued at $226,208,400. This represents a 0.09% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders sold a total of 49,800 shares of company stock valued at $7,487,943 over the last ninety days. Corporate insiders own 13.70% of the company's stock.

Krystal Biotech Stock Down 1.0%

Krystal Biotech stock traded down $1.35 during trading hours on Wednesday, hitting $136.00. The stock had a trading volume of 528,686 shares, compared to its average volume of 419,441. The stock has a market cap of $3.94 billion, a price-to-earnings ratio of 27.64 and a beta of 0.70. The business's 50 day simple moving average is $141.24 and its 200-day simple moving average is $155.67. Krystal Biotech, Inc. has a one year low of $122.80 and a one year high of $207.84.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its earnings results on Monday, August 4th. The company reported $1.29 earnings per share for the quarter, topping analysts' consensus estimates of $1.08 by $0.21. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%. The firm had revenue of $96.04 million for the quarter, compared to analyst estimates of $95.42 million. Research analysts anticipate that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

KRYS has been the topic of several research reports. Citigroup restated a "neutral" rating and issued a $166.00 price target (down from $176.00) on shares of Krystal Biotech in a research note on Tuesday. Bank of America dropped their price target on shares of Krystal Biotech from $193.00 to $192.00 and set a "buy" rating for the company in a research report on Tuesday, July 22nd. HC Wainwright reiterated a "buy" rating and set a $240.00 target price on shares of Krystal Biotech in a research report on Friday, July 25th. Chardan Capital reaffirmed a "buy" rating and set a $219.00 price objective on shares of Krystal Biotech in a research report on Tuesday. Finally, Guggenheim dropped their target price on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $210.22.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).